Becton Dickinson reports positive trial results for Revello stent
Becton Dickinson said its Revello Vascular Covered Stent met a primary composite safety and effectiveness endpoint at nine months in a trial for iliac artery disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
BD reports positive AGILITY trial results for Revello stent
BD said nine-month data from the iliac cohort of its AGILITY trial met the primary composite endpoint and showed high vessel patency, low reintervention rates and no device- or procedure-related deaths.